Get the Weekly Intelligence Brief — top committee picks every Sunday.

EXEL vs SLN

Exelixis vs Silence Therapeutics plc — AI-powered side-by-side comparison
EXEL
Exelixis
67
Buy
VS
SLN
Silence Therapeutics plc
48
Watch
MetricEXELSLN
AI Score 67 48
Price $51.30 $14.69
P/E Ratio 15.60× -6.72×
ROE 36.2% -142.2%
Revenue Growth YoY
Gross Margin 96.5% 68.6%
Debt / Equity 0.09× 0.00×
Dividend Yield 0.0% 0.0%
RSI (14) 41.0 74.4
Beta 0.422 1.351
Expected Upside +8.7%

AI Committee View

Current Innellis committee reasoning for EXEL versus SLN.
EXEL leads by 19 points.

EXEL scores 67/100 (Buy) versus SLN at 48/100 (Watch).

EXEL Committee View
67% agreement
6 analysts

The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 42.5% shows genuine earnings power backing the valuation — Value
  • EPS growing 52.7% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
  • Price-to-book of 5.4x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
SLN Committee View
50% agreement
6 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • MACD histogram positive -- bullish momentum — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • ROE of only -103.3% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
  • Revenue declining -99.3% YoY -- this is not a growth story right now — Growth
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
EXEL Full Analysis SLN Full Analysis